{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "![image.png](data:image/png;base64,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)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# 🚀 JohnSnowLabs Medical LLM Inference Server"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 🔄 The images required to run the llm have been pulled from \n",
    " 👉 [Docker Hub](https://hub.docker.com/r/johnsnowlabs/jsl-llms):\n",
    "\n",
    "\n",
    "### 🐳 The containers are running at system startup\n",
    "\n",
    "\n",
    "Check running the containers with:\n",
    "\n",
    "```bash\n",
    "docker ps\n",
    "```\n",
    "It should show 2 containers running, johnsnowlabs/jsl-llms:marketplace runs the model. \n",
    "ghcr.io/open-webui/open-webui:main runs webui to interact with the model.\n",
    "\n",
    "```\n",
    "CONTAINER ID   IMAGE                                COMMAND                  CREATED      STATUS                            PORTS                                         NAMES\n",
    "4dbe81768b8b   johnsnowlabs/jsl-llms:marketplace    \"./entrypoint.sh --m…\"   2 days ago   Up 2 minutes (health: starting)   0.0.0.0:8080->8080/tcp, [::]:8080->8080/tcp   med-llm-cmp-jsl-llms-1\n",
    "684bf3801bf8   ghcr.io/open-webui/open-webui:main   \"bash start.sh\"          2 days ago   Up 2 minutes (healthy)            0.0.0.0:3000->8080/tcp, [::]:3000->8080/tcp   open-webui\n",
    "```\n",
    "---\n",
    "\n",
    "### 📜 View Container Logs\n",
    "\n",
    "You can monitor the container logs with:\n",
    "\n",
    "```bash\n",
    "docker logs <container-id>\n",
    "```\n",
    "\n",
    "The logs will show important information such as:\n",
    "- Model initialization and loading progress\n",
    "- License validation status\n",
    "- Server startup confirmation\n",
    "- Memory usage and GPU configuration\n",
    "- Model task capabilities\n",
    "- Available API endpoints and routes\n",
    "- Health check status\n",
    "\n",
    "\n",
    "Example log entry for successful startup of johnsnowlabs/jsl-llms:marketplace:\n",
    "```bash\n",
    "INFO: Application startup complete.\n",
    "llm-service [INFO] Server is healthy and model is loaded\n",
    "INFO: Started server process [1]\n",
    "INFO:     127.0.0.1:42154 - \"GET /health HTTP/1.1\" 200 OK\n",
    "```\n",
    "\n",
    "Once you see these messages, the service is ready to accept requests! 🎉"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Imports"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "import json\n",
    "import requests"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Initial setup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "prompt1 = \"How do emerging mRNA technologies compare to traditional vaccine approaches for disease prevention?\"\n",
    "\n",
    "prompt2 = \"\"\"Patients with xeroderma pigmentosum develop skin cancer when they are exposed to sunlight because they have a deficiency in:\n",
    "\n",
    "A. An enzyme essential to repair mismatched bases.\n",
    "B. UV specific endonuclease.\n",
    "C. DNA polymerase I.\n",
    "D. DNA polymerase III.\n",
    "E. Glycosylase that removes uracil bases from DNA.\"\"\"\n",
    "\n",
    "system_prompt = \"\"\"You are a medical expert that reviews the problem, does reasoning, and then gives a final answer.\n",
    "Strictly follow this exact format for giving your output:\n",
    "\n",
    "<think>\n",
    "reasoning steps\n",
    "</think>\n",
    "\n",
    "**Final Answer**: [Conclusive Answer]\"\"\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Health & Version:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Health: 200 \n"
     ]
    }
   ],
   "source": [
    "url = \"http://localhost:8080/health\"\n",
    "response = requests.get(url)\n",
    "print(\"Health:\", response.status_code, response.text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Ping: 200 \n"
     ]
    }
   ],
   "source": [
    "url = \"http://localhost:8080/ping\"\n",
    "response = requests.post(url)\n",
    "print(\"Ping:\", response.status_code, response.text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Version: {'version': '0.7.3'}\n"
     ]
    }
   ],
   "source": [
    "url = \"http://localhost:8080/version\"\n",
    "response = requests.get(url)\n",
    "print(\"Version:\", response.json())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Core Functionality:"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### List available models"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Models: {'object': 'list', 'data': [{'id': 'Medical-Reasoning-LLM-14B', 'object': 'model', 'created': 1744013042, 'owned_by': 'vllm', 'root': 'Medical-Reasoning-LLM-14B', 'parent': None, 'max_model_len': 32768, 'permission': [{'id': 'modelperm-c3ca91b2243847c8986f1cee88189fd8', 'object': 'model_permission', 'created': 1744013042, 'allow_create_engine': False, 'allow_sampling': True, 'allow_logprobs': True, 'allow_search_indices': False, 'allow_view': True, 'allow_fine_tuning': False, 'organization': '*', 'group': None, 'is_blocking': False}]}]}\n"
     ]
    }
   ],
   "source": [
    "url = \"http://localhost:8080/v1/models\"\n",
    "response = requests.get(url)\n",
    "print(\"Models:\", response.json())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Non-Streaming Responses"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "def get_completion_response(url, payload):\n",
    "    \"\"\"\n",
    "    Handles non-streaming responses from both `/v1/chat/completions` and `/v1/completions`.\n",
    "\n",
    "    Args:\n",
    "        url (str): The endpoint URL.\n",
    "        payload (dict): The request payload.\n",
    "\n",
    "    Returns:\n",
    "        str: The generated text (chat or completion).\n",
    "    \"\"\"\n",
    "    response = requests.post(url, json=payload)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        data = response.json()\n",
    "        choices = data.get(\"choices\", [{}])\n",
    "\n",
    "        if \"message\" in choices[0]:\n",
    "            return choices[0][\"message\"].get(\"content\", \"\")\n",
    "\n",
    "        return choices[0].get(\"text\", \"\")\n",
    "    else:\n",
    "        print(\"Error:\", response.status_code, response.text)\n",
    "        return \"\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Chat completions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<think>\n",
      "Emerging mRNA technologies represent a significant advancement in vaccine development, offering several advantages over traditional vaccine approaches, such as live-attenuated, inactivated, and subunit vaccines. Here’s a comparative analysis:\n",
      "\n",
      "### Mechanism of Action\n",
      "- **mRNA Vaccines**: These vaccines introduce a small piece of the genetic code (mRNA) that instructs cells to produce a specific viral protein. The immune system then recognizes this protein as foreign and mounts a protective response.\n",
      "- **Traditional Vaccines**: These vaccines typically introduce either weakened (attenuated) or killed (inactivated) pathogens, or specific proteins/subunits derived from the pathogen.\n",
      "\n",
      "### Development Speed and Flexibility\n",
      "- **mRNA Vaccines**: mRNA vaccines can be developed more rapidly and with greater flexibility. The genetic sequence of a new pathogen can be quickly identified and used to create an mRNA vaccine, potentially allowing for quicker responses to emerging threats.\n",
      "- **Traditional Vaccines**: The development process for traditional vaccines is more time-consuming, often requiring the isolation and cultivation of pathogens, which can take months to years.\n",
      "\n",
      "### Safety Profile\n",
      "- **mRNA Vaccines**: mRNA vaccines are generally considered safe because they do not contain infectious material. The mRNA degrades quickly and does not enter the nucleus of the cell, avoiding integration into the genome.\n",
      "- **Traditional Vaccines**: While generally safe, live-attenuated vaccines can theoretically revert to a virulent form, and inactivated or subunit vaccines may carry risks associated with adjuvants or other components.\n",
      "\n",
      "### Immunogenicity\n",
      "- **mRNA Vaccines**: mRNA vaccines can induce robust immune responses, including both humoral (antibody production) and cellular immunity (T-cell responses). This comprehensive immunity can provide better protection against the target pathogen.\n",
      "- **Traditional Vaccines**: The type of immunity induced depends on the vaccine type. Live-attenuated vaccines often induce stronger and more comprehensive immunity, while inactivated or subunit vaccines may require multiple doses to achieve optimal protection.\n",
      "\n",
      "### Scalability and Production\n",
      "- **mRNA Vaccines**: mRNA vaccines can be produced using relatively straightforward processes involving fermentation and chemical synthesis, making them scalable for large-scale production.\n",
      "- **Traditional Vaccines**: Traditional vaccines may require more complex manufacturing processes, such as growing large quantities of pathogens, which can be resource-intensive and time-consuming.\n",
      "\n",
      "### Storage and Distribution\n",
      "- **mRNA Vaccines**: Some mRNA vaccines require ultracold storage conditions, which can pose logistical challenges for distribution, especially in regions with limited infrastructure.\n",
      "- **Traditional Vaccines**: Many traditional vaccines can be stored at standard refrigeration temperatures, making them easier to distribute globally.\n",
      "\n",
      "### Efficacy Against Mutations\n",
      "- **mRNA Vaccines**: The ability to quickly update the mRNA sequence to target emerging variants makes mRNA vaccines particularly advantageous for combating rapidly evolving pathogens like SARS-CoV-2.\n",
      "- **Traditional Vaccines**: Modifying traditional vaccines to target new variants can be more time-consuming, often requiring new manufacturing batches and potentially new clinical trials.\n",
      "\n",
      "### Long-Term Effects\n",
      "- **mRNA Vaccines**: As mRNA vaccines are a relatively new technology, more research is needed to fully understand their long-term effects and potential for immune memory.\n",
      "- **Traditional Vaccines**: Traditional vaccines have a longer track record, with well-documented long-term effects and established immunity.\n",
      "\n",
      "### Cost and Accessibility\n",
      "- **mRNA Vaccines**: The initial development and production costs for mRNA vaccines can be high, but once established, they may offer cost savings and improved accessibility, especially for emerging pathogens.\n",
      "- **Traditional Vaccines**: The costs associated with traditional vaccines vary, but they have been widely used and integrated into healthcare systems, making them accessible in many regions.\n",
      "\n",
      "### Conclusion\n",
      "While traditional vaccine approaches have proven effective and reliable over decades, mRNA technologies offer several compelling advantages, particularly in terms of speed, flexibility, and potential for inducing robust and comprehensive immune responses. However, the integration of mRNA vaccines into global immunization strategies will depend on addressing challenges related to storage, regulatory approval, and public acceptance.\n",
      "</think>\n",
      "\n",
      "**Final Answer**: mRNA technologies offer several advantages over traditional vaccines, including faster development, robust immune responses, and adaptability to new variants. However, they also face challenges like stringent storage requirements. Both approaches have their strengths and are likely to coexist and complement each other in disease prevention.\n"
     ]
    }
   ],
   "source": [
    "url = \"http://localhost:8080/v1/chat/completions\"\n",
    "payload = {\n",
    "    \"model\": \"Medical-LLM-Small\",\n",
    "    \"messages\": [\n",
    "        {\"role\": \"system\", \"content\": system_prompt},\n",
    "        {\"role\": \"user\", \"content\": prompt1}\n",
    "    ],\n",
    "    \"max_tokens\": 2048,\n",
    "    \"temperature\": 0.8,\n",
    "    \"top_p\": 0.95,\n",
    "}\n",
    "\n",
    "response = get_completion_response(url, payload)\n",
    "print(response)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "For additional parameters and details, refer to:\n",
    "\n",
    "- [ChatCompletionRequest](https://github.com/vllm-project/vllm/blob/v0.8.5/vllm/entrypoints/openai/protocol.py#L232)\n",
    "- [OpenAI’s Chat Completions API](https://platform.openai.com/docs/api-reference/chat/create)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Text completions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " <think>\n",
      "Xeroderma pigmentosum is a rare genetic disorder characterized by an inability to repair DNA damage caused by ultraviolet (UV) light. This results in severe sensitivity to sunlight and an increased risk of developing skin cancers. The underlying cause of this condition is a deficiency in enzymes involved in the nucleotide excision repair (NER) pathway.\n",
      "\n",
      "The NER pathway involves several key enzymes, including UV-specific endonucleases. These endonucleases are responsible for recognizing and cutting out damaged sections of DNA, allowing for the repair process to proceed. In patients with xeroderma pigmentosum, the absence or dysfunction of these endonucleases leads to the accumulation of DNA damage, particularly from UV exposure, which in turn predisposes them to the development of skin cancers.\n",
      "\n",
      "Given the options provided:\n",
      "A. An enzyme essential to repair mismatched bases - This refers to the mismatch repair pathway, which is not directly involved in repairing UV-induced DNA damage.\n",
      "B. UV specific endonuclease - This is the correct answer, as the deficiency in UV-specific endonucleases is a hallmark of xeroderma pigmentosum.\n",
      "C. DNA polymerase I - This enzyme is involved in DNA replication and repair, but it is not the specific enzyme deficient in xeroderma pigmentosum.\n",
      "D. DNA polymerase III - This enzyme is also involved in DNA replication, not specifically in the repair of UV-induced damage.\n",
      "E. Glycosylase that removes uracil bases from DNA - This enzyme is involved in base excision repair, not nucleotide excision repair.\n",
      "\n",
      "Therefore, the correct answer is B.\n",
      "</think>\n",
      "\n",
      "**Final Answer**: [Conclusive Answer] B. UV specific endonuclease.\n"
     ]
    }
   ],
   "source": [
    "url = \"http://localhost:8080/v1/completions\"\n",
    "payload = {\n",
    "    \"model\": \"Medical-LLM-Small\",\n",
    "    \"prompt\": f\"{system_prompt}\\n\\nUser: {prompt2}\\n\\nAssistant:\",\n",
    "    \"max_tokens\": 2048,\n",
    "    \"temperature\": 0.8,\n",
    "    \"top_p\": 0.95,\n",
    "}\n",
    "\n",
    "response = get_completion_response(url, payload)\n",
    "print(response)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "For further details and additional parameters, see:\n",
    "\n",
    "- [CompletionRequest](https://github.com/vllm-project/vllm/blob/v0.8.5/vllm/entrypoints/openai/protocol.py#L730)\n",
    "- [OpenAI’s Completions API](https://platform.openai.com/docs/api-reference/completions/create)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Streaming Responses"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "def stream_response(url, payload):\n",
    "    \"\"\"\n",
    "    Handles streaming responses from both `/v1/chat/completions` and `/v1/completions`.\n",
    "\n",
    "    Args:\n",
    "        url (str): The API endpoint URL.\n",
    "        payload (dict): The JSON payload for the request.\n",
    "\n",
    "    Prints the reconstructed streamed output in real-time.\n",
    "    \"\"\"\n",
    "    response = requests.post(url, json=payload, stream=True)\n",
    "\n",
    "    for chunk in response.iter_lines():\n",
    "        if chunk:\n",
    "            decoded = chunk.decode(\"utf-8\")\n",
    "            if decoded.startswith(\"data: \"):\n",
    "                data = decoded[len(\"data: \"):]\n",
    "                if data.strip() == \"[DONE]\":\n",
    "                    break\n",
    "                try:\n",
    "                    parsed = json.loads(data)\n",
    "                    choices = parsed.get(\"choices\", [])\n",
    "                    if not choices:\n",
    "                        continue\n",
    "                    choice = choices[0]\n",
    "\n",
    "                    content = choice.get(\"delta\", {}).get(\"content\") or choice.get(\"text\")\n",
    "                    if content:\n",
    "                        print(content, end=\"\", flush=True)\n",
    "                except (KeyError, json.JSONDecodeError):\n",
    "                    continue\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Chat completions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<think>\n",
      "Emerging mRNA technologies represent a significant advancement in vaccine development, offering several advantages over traditional approaches like inactivated, attenuated, or subunit vaccines. Here's a comparison:\n",
      "\n",
      "1. **Mechanism of Action**:\n",
      "   - **mRNA Vaccines**: These vaccines deliver a small piece of genetic material (mRNA) into cells, instructing them to produce a harmless piece of a virus or bacteria. This mimics an infection and teaches the immune system to recognize and fight the actual pathogen.\n",
      "   - **Traditional Vaccines**: Traditional vaccines can include inactivated or attenuated whole viruses, purified proteins (subunits), or parts of the virus/bacteria. These methods aim to elicit an immune response without causing the disease.\n",
      "\n",
      "2. **Safety and Efficacy**:\n",
      "   - **mRNA Vaccines**: mRNA vaccines have demonstrated high efficacy and safety profiles. They are non-infectious and cannot integrate into the genome, reducing the risk of adverse effects.\n",
      "   - **Traditional Vaccines**: Traditional vaccines have a long history of safety and efficacy but can sometimes cause side effects, such as fever or allergic reactions, especially with whole inactivated or live-attenuated vaccines.\n",
      "\n",
      "3. **Development Speed**:\n",
      "   - **mRNA Vaccines**: The modular nature of mRNA vaccines allows for rapid design and manufacturing. This speed was evident during the development of COVID-19 vaccines, which were produced and approved within months.\n",
      "   - **Traditional Vaccines**: Developing new traditional vaccines can take years due to the need for extensive trials and manufacturing processes.\n",
      "\n",
      "4. **Storage and Distribution**:\n",
      "   - **mRNA Vaccines**: Currently, mRNA vaccines like those for COVID-19 require ultra-cold storage (around -70°C), which can be challenging for distribution in some regions. However, newer formulations aim to improve stability.\n",
      "   - **Traditional Vaccines**: Many traditional vaccines can be stored at refrigerated temperatures (2-8°C), making them more accessible in various settings.\n",
      "\n",
      "5. **Versatility**:\n",
      "   - **mRNA Vaccines**: mRNA technology is highly adaptable and can be easily modified to target new pathogens or variants. This flexibility allows for quick responses to emerging threats.\n",
      "   - **Traditional Vaccines**: While traditional vaccines can be adapted, the process typically involves more time and resources compared to mRNA vaccines.\n",
      "\n",
      "6. **Immune Response**:\n",
      "   - **mRNA Vaccines**: mRNA vaccines stimulate both antibody and T-cell responses, providing a balanced immune protection.\n",
      "   - **Traditional Vaccines**: The type of immune response varies depending on the vaccine. Some may primarily stimulate antibodies, while others enhance cellular immunity.\n",
      "\n",
      "7. **Manufacturing Scalability**:\n",
      "   - **mRNA Vaccines**: mRNA vaccines can be produced using established biotechnological methods, allowing for scalable manufacturing processes.\n",
      "   - **Traditional Vaccines**: Production methods for traditional vaccines can vary, and scaling up can be more complex, especially for live-attenuated vaccines.\n",
      "\n",
      "In summary, while traditional vaccines have proven their worth over decades, mRNA technologies offer a rapid, flexible, and potentially more adaptable approach to vaccine development. However, the choice between mRNA and traditional vaccines often depends on the specific disease, available resources, and logistical considerations.\n",
      "</think>\n",
      "\n",
      "**Final Answer**: Emerging mRNA technologies offer several advantages over traditional vaccine approaches. They are faster to develop, more adaptable, and can elicit both antibody and T-cell responses. However, they currently require ultra-cold storage, which can be a logistical challenge. Traditional vaccines, while slower to produce, are widely established and effective, with varied storage requirements."
     ]
    }
   ],
   "source": [
    "url = \"http://localhost:8080/v1/chat/completions\"\n",
    "\n",
    "payload = {\n",
    "    \"model\": \"Medical-LLM-Small\",\n",
    "    \"messages\": [\n",
    "        {\"role\": \"system\", \"content\": system_prompt},\n",
    "        {\"role\": \"user\", \"content\": prompt1}\n",
    "    ],\n",
    "    \"max_tokens\": 2048,\n",
    "    \"temperature\": 0.8,\n",
    "    \"top_p\": 0.95,\n",
    "    \"stream\": True\n",
    "}\n",
    "\n",
    "stream_response(url, payload)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Text completions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " <think>\n",
      "Xeroderma pigmentosum (XP) is a rare genetic disorder characterized by extreme sensitivity to ultraviolet (UV) light. People with XP are at high risk of developing skin cancer and other skin damage because their cells have an impaired ability to repair DNA damage caused by UV radiation.\n",
      "\n",
      "The primary mechanism underlying XP is a deficiency in the nucleotide excision repair (NER) pathway. This repair pathway is responsible for recognizing and removing bulky DNA lesions, such as those formed by UV light. In XP, mutations in genes encoding proteins involved in the NER pathway lead to an inability to efficiently repair these lesions, resulting in the accumulation of DNA damage.\n",
      "\n",
      "The NER pathway involves multiple steps, including the recognition of damaged DNA, the unwinding of the DNA helix around the lesion, the removal of the damaged segment, and the synthesis of the replacement DNA. A key component of this pathway is the endonuclease that specifically recognizes and cleaves the damaged DNA strand to facilitate repair.\n",
      "\n",
      "Among the options provided:\n",
      "- **A. An enzyme essential to repair mismatched bases**: This refers to the mismatch repair (MMR) pathway, which corrects errors that occur during DNA replication. While important, it is not directly responsible for repairing UV-induced DNA damage.\n",
      "- **B. UV specific endonuclease**: This refers to the endonuclease activity that recognizes UV-induced lesions and initiates the NER pathway. This is the correct answer because XP patients lack this specific endonuclease activity.\n",
      "- **C. DNA polymerase I**: This enzyme is involved in DNA replication and repair but is not specific to UV damage repair.\n",
      "- **D. DNA polymerase III**: This is the primary replicative DNA polymerase in bacteria and eukaryotes but is not specific to UV damage repair.\n",
      "- **E. Glycosylase that removes uracil bases from DNA**: This enzyme is involved in base excision repair (BER), which is responsible for removing small, chemically altered bases, not UV-induced bulky adducts.\n",
      "\n",
      "Given this information, the deficiency in XP that leads to increased susceptibility to UV-induced skin cancer is due to the lack of a UV-specific endonuclease, which is a component of the NER pathway.\n",
      "</think>\n",
      "\n",
      "**Final Answer**: B. UV specific endonuclease."
     ]
    }
   ],
   "source": [
    "url = \"http://localhost:8080/v1/completions\"\n",
    "\n",
    "payload = {\n",
    "    \"model\": \"Medical-LLM-Small\",\n",
    "    \"prompt\": f\"{system_prompt}\\n\\nUser: {prompt2}\\n\\nAssistant:\",\n",
    "    \"max_tokens\": 2048,\n",
    "    \"temperature\": 0.8,\n",
    "    \"top_p\": 0.95,\n",
    "    \"stream\": True\n",
    "}\n",
    "\n",
    "stream_response(url, payload)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "\n",
    "## Additional Endpoints  \n",
    "You can access other API routes depending on the model's capabilities. Check your server startup logs for supported tasks and their corresponding endpoints.\n",
    "\n",
    "The full list of available routes is logged during service initialization."
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "conda_pytorch_p310",
   "language": "python",
   "name": "conda_pytorch_p310"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
